BioNTech said that its VEGF bispecific sets it apart from competitors because of its mechanism and how it plans to ...

A team from The Institute of Cancer Research, London, has developed a new immuno-PET imaging technique that could spot which ...

A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses.

NEW YORK – Akeso Biopharma on Wednesday said it dosed the first patient with PD-L1-positive advanced head and neck cancer in a Phase III trial, comparing the activity of its PD-1/VEGF bispecific ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

The global PD-L1 biomarker testing market is experiencing remarkable growth, fueled by the increasing demand for personalized ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung ...

Mutation-directed targeted therapy in combination with a PD-L1 inhibitor “is a promising strategy” to extend survival in patients with anaplastic thyroid cancer, according to researchers.

Researchers from Zhejiang Jieyuan Med-Tech Co. Ltd. and collaborators have reported the design and preclinical characterization of a novel series of benzylamine derivatives acting as PD-1/PD-L1 ...

Patients with TNBC and HR+/HER2- breast cancer demonstrated safe treatment with preoperative radiation therapy with Keytruda.

TACTI-003 Cohort B: Eftilagimod Alpha (Soluble LAG-3) and Pembrolizumab in First-Line Recurrent or Metastatic Head & Neck ...